Considering Fedratinib or Ruxolitinib in the Frontline Setting for Treatment of Myelofibrosis
Ruben Mesa, MD, discusses his experience with fedratinib since its FDA approval for the treatment of patients with myelofibrosis. The agent is compared across trials with ruxolitinib, which has been approved for several years in this space.
Ruben Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses his experience with fedratinib (Inrebic) since its FDA approval for the treatment of patients with myelofibrosis (MF). The agent is compared across trials with ruxolitinib (Jakafi), which has been approved for several years in this space.
The most immediate impact for the approval of fedratinib is for the treatment of patients with MF who have not had an optimal response to ruxolitinib or who have lost their response and now may benefit from a new agent, says Mesa. However, there has not been a head-to-head comparison between these 2 agents. Both fedratinib and ruxolitinib have had very positive phase III studies, though their toxicity profiles are slightly different.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
